Evidence map›Paper›PMID 42681619›Full record

Observational studyBMC cancer2026

Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [

Mariam Amghar, Thomas Hielscher, Tobias Rausch, Hilal Özgür, Ulrike Bauder-Wüst, Hendrik Rathke, Frank Bruchertseifer, Alfred Morgenstern, Mareike Roscher, Vladimír Beneš and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mariam AmgharResearch Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Thomas HielscherDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Tobias RauschGenomics Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Hilal ÖzgürGenomics Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Ulrike Bauder-WüstResearch Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hendrik RathkeCantonal Hospital Grisons, Chur, Switzerland.
Frank BruchertseiferEuropean Commission, Joint Research Centre (JRC), Karlsruhe, Germany.
Alfred MorgensternEuropean Commission, Joint Research Centre (JRC), Karlsruhe, Germany.
Mareike RoscherService Unit Radiopharmaceuticals and Preclinical Studies, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Vladimír BenešGenomics Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Clemens KratochwilDepartment of Nuclear Medicine, University Hospital, Heidelberg, Germany.
Martina Benešová-SchäferResearch Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.benesova@dkfz-heidelberg.de.ORCID https://orcid.org/0000-0002-8926-5376

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT) demonstrates clinical efficacy in metastatic castration-resistant prostate cancer (mCRPC), yet robust biomarkers for dynamic treatment monitoring and resistance remain lacking. We investigated circulating tumor DNA (ctDNA)-derived tumor fraction (TFx) and genome-wide copy-number alterations (CNAs) as non-invasive biomarkers of treatment response and resistance biology.

methodsSeventy-eight patients with advanced mCRPC receiving tandem [

resultsBaseline TFx differed across metastatic disease stages (p = 0.027) and dynamic TFx changes paralleled PSA kinetics during early treatment. Modelled as a time-dependent variable, TFx was associated with a significantly increased risk of progression (HR 4.9, 95% CI 1.2-20.1, p = 0.026). Unsupervised clustering identified distinct high- and low-CNA burden groups strongly correlated with TFx (p = 8.09 × 10⁻

conclusionsctDNA-derived TFx represents a dynamic biomarker of treatment response and progression risk, while CNA profiling provides insight into resistance mechanisms in mCRPC treated with PSMA-RLT. These findings support the integration of ctDNA-based biomarkers into clinical stratification and real-time monitoring strategies.

Indexed as

ActiniumCirculating Tumor DNADipeptidesDNA Copy Number VariationsHeterocyclic Compounds, 1-RingProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overBiomarkers, TumorHumansMaleMiddle AgedNeoplasm MetastasisPrognosisProspective StudiesProstate-Specific Antigen(225)Ac-PSMA-617ActiniumBiomarkers, TumorCirculating Tumor DNADipeptidesHeterocyclic Compounds, 1-RingProstate-Specific AntigenCopy-number alterationsctDNAPSMA-617Radioligand therapyTumor fraction

Identifiers

PMID42681619
PMCPMC13531912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.